Ventracor has made great progress in the last few months, and we are poised for major expansion as the year develops. Key milestones achieved include:
* CE Mark approval to market in Europe ? December 2006 * FDA grants conditional approval for Destination Therapy (DT) Clinical Trial protocol ? December 2006 * Feasibility Study ? 10 patient enrolment achieved ? January 2007 * FDA agreement to extension of Feasibility Trial * FDA agrees to US Bridge to Transplant (BTT) Pivotal Trial protocol, unconditional approval granted ? January 2007 * Australian Government approval of Commercial Ready Grant ? January 2007
A full copy of the document sent to all shareholders is attached. It is also available at